Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus VIBATIV.
COR-OTICIN vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
1-2 drops in each affected ear twice daily for 7 days.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Renal (60-80% unchanged), fecal/biliary (5-10%)
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic